A Phase 1/2 interventional study of Period 1 GX-30, Period 2 THYROGEN® and Period 1 THYROGEN®, Period 2 GX-30 in Total Thyroidectomy and Near-total Thyroidectomy, sponsored by Genexine, Inc.. Completed at 5 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2020-09-09.
Sponsored by Genexine, Inc. · Phase 1/2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing Thyrotropin Alfa in Thyroid Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Thyrotropin Alfa · Thyroid Neoplasms.
Among the 11 studies testing Thyrotropin Alfa in Thyroid Neoplasms, this one is the 10th largest by enrollment, is the only one that started in 2017, is one of 2 in phase 1/2, and was the 6th registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.
Browse Thyroid Neoplasms studies →1 of the 11 studies testing Thyrotropin Alfa in Thyroid Neoplasms is open now, in 1 country. Recruiting first, the newest first:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–90
By country, each count listing its studies:
Thyrotropin Alfa: first FDA approval 1998 (THYROGEN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 4 · Phase 4 2
First in 1997; this study’s year is marked. 1 started in 2017.
This study's enrollment of 8 is below the median of 54 across 520 interventional studies indexed under Thyroid Neoplasms.
Median enrollment 63 across the 11 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 7 most frequent:
Genexine, Inc. is the lead sponsor of 36 studies on the registry; 1 is open to participants now.
Genexine, Inc. has 1 study filed under Thyroid Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing Thyrotropin Alfa in Thyroid Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed as a combination of phase 1 (Part A) and phase 2 (Part B). The purpose of Part A was to determine the safety, tolerability, and pharmacokinetics in patients with total thyroidectomy or near total thyroidectomy of GX-30 and it has been completed. The Part B is currently recruiting and will investigate the efficacy and safety of GX-30 compared with THYROGEN®.
Recombinant human TSH was developed to provide TSH stimulation without withdrawal of thyroid hormone. Radioiodine ablation and diagnosis with rhTSH became the standard of care treatment for patients with differentiated thyroid cancer. Stably supplying rhTSH has been the unmet need for management and follow-up procedure for thyroid remnant. GX-30 is an investigational product, developed to provide inexpensive rhTSH to patients in order to ensure stable supply of rhTSH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection
Drug: Period 1 GX-30, Period 2 THYROGEN®
Period 1 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection
Drug: Period 1 THYROGEN®, Period 2 GX-30
Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.
Also known as: Thyrotropin alpha
Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.
Also known as: Thyrotropin alpha
Efficacy (Part B)
I-123 Whole body scan image classification
Time frame: at each Day 4, period 1 and period 2.
TSH concentration (Part B)
TSH concentration for Pharmacokinetics assessment
Time frame: Baseline, Day 1 to Day 8.
ADA (Part B)
Anti-Drug Antibody detection
Time frame: Baseline, Day 1 and 15 of Period 2
Tg concentration (Part B)
Thyroglobulin concentration for secondary efficacy assessment
Time frame: Baseline, Day 1 to Day 5
T3, free T4 concentration (Part B)
Thyroid hormones concentration for pharmacodynamic assessment
Time frame: Baseline, Day 1, 2, 5 of each period and Day 15 of period 2.
Adverse events (Part B)
Safety assessment
Time frame: through study completion, average of 6 weeks.
Plan to share: No
Ran from Sep 2017 to primary completion in Jan 2020, 28 months.
Of 21 phase 1/2 interventional studies under Thyroid Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 28 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Thyrotropin Alfa